Private Equity Firm Financial Services

QHP Capital

Raleigh, North Carolina, United States

Formerly known as NovaQuest Capital Management, NovaQuest Capital Management, LLC, NovaQuest Private Equity

Biopharma and life sciences investment firm providing product finance (at-risk, nondilutive funding) and private equity growth capital to advance partner companies’ clinical trials, launch new brands, license products, and acquire accretive assets or companies.

Focus Areas
Biopharma / life sciences private equity, Product finance, Growth capital
Website
novaquest.com

Tracked deals

5

5 tracked deals across 2019-2022.

Recent pace

0

0 tracked deals announced in the last 12 months.

Deal mix

Addon

3 addon · 1 buyout · 1 growth capital

QHP Capital Acquisition Volume by Year

Last 4 years

Acquisition volume by year Annual acquisition counts for the last 4 years for QHP Capital. 1 2019 1 2020 2 2021 1 2022

Supporting Data

Recent Transactions

  • Catalyst Clinical Research Acquires Aptus Clinical
    May 4, 2022
    Buyer
    Catalyst Clinical Research, NovaQuest Capital Management, LLC
    Target
    Aptus Clinical
    Industry
    Healthcare Services
    Location
    Cheshire, United Kingdom
    Type
    Addon

    Catalyst Clinical Research, a portfolio company of NovaQuest Capital Management, has acquired U.K.-based Aptus Clinical to accelerate Catalyst's European expansion and broaden its oncology and early-phase clinical services. The deal creates a multi-region CRO operating across North America and Europe, increases Catalyst's patient reach by nearly 600 and lifts combined headcount to more than 800.

  • NovaQuest Capital Management Acquires TechAccel's Stake in Covenant Animal Health Partners
    November 30, 2021
    Buyer
    NovaQuest Capital Management
    Target
    Covenant Animal Health Partners
    Seller
    TechAccel LLC
    Industry
    Veterinary
    Location
    North Carolina, United States
    Type
    Buyout

    NovaQuest Capital Management has acquired TechAccel LLC's ownership stake in Covenant Animal Health Partners, a development and registration partnership focused on revenue-ready animal health products. The move gives NovaQuest full ownership (or increased control) of Covenant to expand its animal health development capabilities and advance new assets into industry partner portfolios.

  • Azurity Pharmaceuticals to Acquire and Merge with Arbor Pharmaceuticals
    September 24, 2021
    Buyer
    Azurity Pharmaceuticals, Inc., NovaQuest Private Equity
    Target
    Arbor Pharmaceuticals, Inc.
    Seller
    JW Asset Management, KKR
    Industry
    Pharmaceuticals
    Location
    Georgia, United States
    Type
    Addon

    Azurity Pharmaceuticals, majority-owned by NovaQuest Private Equity, has entered into a definitive agreement to acquire Arbor Pharmaceuticals from existing investors including JW Asset Management and KKR. The companies will merge and operate as Azurity, creating a larger specialty pharmaceuticals business with an expanded portfolio across neuroscience, cardiovascular, GI, endocrinology and institutional markets; the transaction is expected to close pending regulatory approvals.

  • Catalyst Clinical Research Merges with Ce3, Inc.
    August 5, 2020
    Buyer
    Catalyst Clinical Research, NovaQuest Capital Management, LLC
    Target
    Ce3, Inc.
    Industry
    Healthcare Services
    Location
    Connecticut, United States
    Type
    Addon

    Catalyst Clinical Research, a NovaQuest-backed CRO headquartered in Wilmington, North Carolina, has merged with Ce3, Inc., an early-phase oncology-focused CRO based in Clinton, Connecticut. The transaction combines Ce3's 15+ years of oncology expertise with Catalyst's broader clinical development and technology capabilities to create a next-generation oncology-focused CRO (add-on to Catalyst's NovaQuest-backed platform).

  • InformedDNA Secures Growth Investment from TT Capital Partners, NovaQuest and Frist Cressey Ventures
    December 13, 2019
    Buyer
    TT Capital Partners, NovaQuest Capital Management, Frist Cressey Ventures
    Target
    InformedDNA
    Industry
    Healthcare Services
    Location
    Florida, United States
    Type
    Growth capital

    InformedDNA, the U.S. leader in genetics services, has entered definitive agreements with TT Capital Partners, NovaQuest Capital Management, and Frist Cressey Ventures to receive a growth capital investment to scale its technology-enabled genetic services and expand its genetic counseling staff. Terms were not disclosed; InformedDNA will remain led by CEO David Nixon and has also secured a flexible credit facility from CIBC.

Related Acquisition Pages

Healthcare Services Buyers & Acquisitions 3 tracked deals by QHP Capital. Pharmaceuticals Buyers & Acquisitions 1 tracked deal by QHP Capital. Veterinary Buyers & Acquisitions 1 tracked deal by QHP Capital. Acquisitions in Connecticut 1 tracked deal by QHP Capital. Acquisitions in Florida 1 tracked deal by QHP Capital. Acquisitions in Georgia 1 tracked deal by QHP Capital. Acquisitions in North Carolina 1 tracked deal by QHP Capital.

Related articles

Selling a company? Get in front of buyers like QHP Capital

Turn tracked acquisition activity into an outreach-ready buyer list.

Find buyers like these →